CA2179294A1 - Low molecular weight hyaluronic acid with peptide or protein - Google Patents
Low molecular weight hyaluronic acid with peptide or proteinInfo
- Publication number
- CA2179294A1 CA2179294A1 CA002179294A CA2179294A CA2179294A1 CA 2179294 A1 CA2179294 A1 CA 2179294A1 CA 002179294 A CA002179294 A CA 002179294A CA 2179294 A CA2179294 A CA 2179294A CA 2179294 A1 CA2179294 A1 CA 2179294A1
- Authority
- CA
- Canada
- Prior art keywords
- molecular weight
- hyaluronic acid
- peptide
- protein
- weight hyaluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 5
- 229920002674 hyaluronan Polymers 0.000 title abstract 5
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to freeze dried soft, flexible and continous matrix of low-molecular weight hyaluronic acid or salt thereof, in which the molecular weight of the hyaluronic acid is preferably between 50 000 and 200 000 Da, containing at least one peptide or protein.
It also relates to a pharmaceutical composition in the form of a layer which is characterised by this freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein. The drug is preferably chosen from at least one of GH, IGF-I, IGP-II and/or EGF and could be mixtured with an antibiotic agent. The process for the manufacture of this matrix and the use of the pharmaceutical composition for the manufacturing of a drug for wound healing is claimed. The invention discloses a method for accurately obtaining a predetermined dosage of a topically administerable drug which is characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein to form a layer.
It also relates to a pharmaceutical composition in the form of a layer which is characterised by this freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein. The drug is preferably chosen from at least one of GH, IGF-I, IGP-II and/or EGF and could be mixtured with an antibiotic agent. The process for the manufacture of this matrix and the use of the pharmaceutical composition for the manufacturing of a drug for wound healing is claimed. The invention discloses a method for accurately obtaining a predetermined dosage of a topically administerable drug which is characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein to form a layer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9400036A SE9400036D0 (en) | 1994-01-10 | 1994-01-10 | Low modecular weight hyaluronic acid |
SE9400036-1 | 1994-01-10 | ||
PCT/SE1995/000011 WO1995018635A1 (en) | 1994-01-10 | 1995-01-10 | Low molecular weight hyaluronic acid with peptide or protein |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2179294A1 true CA2179294A1 (en) | 1995-07-13 |
CA2179294C CA2179294C (en) | 2006-12-12 |
Family
ID=37561031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002179294A Expired - Fee Related CA2179294C (en) | 1994-01-10 | 1995-01-10 | Low molecular weight hyaluronic acid with peptide or protein |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2179294C (en) |
-
1995
- 1995-01-10 CA CA002179294A patent/CA2179294C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2179294C (en) | 2006-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1469295A (en) | Low molecular weight hyaluronic acid with peptide or protein | |
US6124273A (en) | Chitin hydrogels, methods of their production and use | |
EP1325754B1 (en) | Wound dressing materials comprising collagen and oxidized cellulose | |
ES2215645T3 (en) | QUICK DISPERSION DOSAGE FORMS CONTAINING FISH GELATINE. | |
US20030212005A1 (en) | Composition and method for growing, protecting, and healing tissues and cells | |
AU632539B2 (en) | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings | |
CA2134348A1 (en) | Polysaccharide derivatives and drug carriers | |
KR890003400A (en) | Bioactive Peptide Powder Composition (Formulation) for Nasal Administration | |
PT94842A (en) | METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROPARTICULES OF A LACTIC AND GLYCOLIC ACID COPOLYMER AND INCORPORATING AS AN ACTIVE SUBSTANCE A PAMOATE, TANATE, ESTEARATE OR PALMITATE OF A NATURAL OR SYNTHETIC PEPTIDE | |
CA2059865A1 (en) | Pharmaceutical Compositions Containing Orally Absorbable Glycosaminoglycans | |
CA2032059A1 (en) | Wound treatment employing biologically active peptides | |
JPS6147413A (en) | Active compound depot agent | |
US6147053A (en) | Combination containing growth factors and polyelectrolytes | |
CA2251281A1 (en) | Drug composition with controlled drug release rate | |
EP0966299B1 (en) | Novel oral formulations of calcitonin | |
AU5283890A (en) | Fibroblast growth factor (fgf)-based stabilized compositions | |
EP0416678A1 (en) | Topical compositions containing Defibrotide | |
CA2179294A1 (en) | Low molecular weight hyaluronic acid with peptide or protein | |
AU762262B2 (en) | Bone cement with antimicrobial peptides | |
AU2001289641A1 (en) | Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses | |
US5314881A (en) | Use of phosphomycin and the pharmaceutically acceptable salts thereof as a topical cicatrizer | |
EP0354714A3 (en) | Pharmaceutical compositions containing polyaromatic compounds | |
EP0137743A3 (en) | Topically administrable pharmaceutical compositions | |
FR2684878B1 (en) | STABILIZED PHARMACEUTICAL COMPOSITION OF RECOMBINANT, NON-GLYCOSYLATED HUMAN IL2 IN REDUCED FORM AND PROCESS FOR PREPARING THE SAME. | |
DE3585936D1 (en) | BIOLOGICALLY ACTIVE PEPTIDES, THEIR METHOD FOR THE PRODUCTION AND PHARMACEUTICAL COMPOSITIONS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |